Lv3
260 积分 2024-10-26 加入
Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis
3小时前
待确认
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
4天前
已完结
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial
17天前
已完结
Beyond the bone marrow: a review of therapeutic approaches for extramedullary disease in multiple myeloma and the significance of MRD assessment
17天前
已关闭
High-Risk Genetic Multiple Myeloma: From Molecular Classification to Innovative Treatment with Monoclonal Antibodies and T-Cell Redirecting Therapies
17天前
已完结
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
17天前
已完结
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses
20天前
已完结
Final outcomes of escalated melphalan 280 mg/m2 with amifostine cytoprotection followed autologous hematopoietic stem cell transplantation for multiple myeloma: high CR and VGPR rates do not translate into improved survival
27天前
已完结
Not too little, not too much—just right! (Better ways to give high dose melphalan)
27天前
已完结
[Updated treatment strategy for transplant-eligible multiple myeloma: current status and future perspectives]
28天前
已关闭
皖公网安备34019202002308
